The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Doc - IFN has been used commercially since the 1980s. What is your point exactly?. Its use is now dramatically falling - see MS and Hep B. There are much better therapies.
My comments on stats was in part playful but there is a serious point. Modern successes like sofosbuvir and tenofovir and triple therapy for HIV really don’t need a statistical analysis to see they are powerful. I have been in the pharmaceutical industry for 40 years.
Look on any analysis this asset has to be worth more to Han its current market valuation- assuming gold stays above 1800. I am certainly going to keep buying at these prices and would like to persuade all enthusiasts to do the same
Identifying bio markers reliably is a major research project. It will be great if it is useful and may unlock the potential of IFN but this sort of research is not easy and the any clinical trial will be particularly challenging